Apyx Medical (APYX) Common Equity (2010 - 2026)

Apyx Medical has reported Common Equity for 17 years, with the latest figure at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 20.56% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 20.56% YoY), and the FY2025 full-year result was $14.5 million, up 1.43% from the prior year.
• Common Equity for Q1 2026 stood at $12.8 million, down from $14.5 million in the prior quarter.
• The five-year high for Common Equity was $49.8 million in Q1 2022, with the low at $5.8 million in Q3 2025.
• Historically, Common Equity has averaged $24.8 million across 5 years, with a median of $20.5 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity slumped 66.66% — and 2026, when it advanced 20.56%.
• Apyx Medical's Common Equity stood at $37.8 million in 2022, then declined by 28.76% to $26.9 million in 2023, then plunged by 46.75% to $14.3 million in 2024, then gained by 1.43% to $14.5 million in 2025, then fell by 11.75% to $12.8 million in 2026.
• The last three Common Equity figures came in at $12.8 million (Q1 2026), $14.5 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.